With no reported revenue and negative earnings, conventional earnings and EV-based multiples are not meaningful for VKTX, leaving price-to-book as the only usable anchor. A 4.73 P/B against a retained deficit of roughly -$1.3B suggests the equity value rests almost entirely on paid-in capital and pipeline expectations rather than demonstrated cash generation. Investors should monitor whether the premium narrows as clinical milestones are reached or whether it compresses if dilution continues.

The low D/E ratio is driven by a large equity base refreshed through external raises rather than by any proven earnings capacity, so it reflects a capital structure built on issuance rather than leverage management. Interest coverage is negative and not informative about debt service comfort, since EBIT is deeply negative. The relevant risk is refinancing or raising capital on dilutive terms if the free cash flow deficit persists, which warrants further investigation.

Headline liquidity looks robust, yet the current ratio is flattered by the absence of current liabilities relative to a large cash position and does not capture burn velocity. At the reported quarterly deficit, the cash balance implies a multi-quarter runway that may shorten quickly as R&D spending scales. Investors should monitor cash runway and the timing of any further equity raises rather than relying on the static ratio.

The decline in ROIC and ROE tracks the expansion of operating losses faster than the growth of the invested capital base, so the ratios are being driven by the margin side of the equation rather than by any efficiency gain. Because no revenue is reported, margins are not meaningful and the ratios simply reflect the scale of spending relative to equity. Investors should monitor whether returns stabilize once spending plateaus, as the current trajectory implies continued value dilution per dollar invested.

VKTX's price-to-book of 4.73 is elevated relative to PEPG at 0.71 and GPCR at 0.79, though closer to KYMR at 7.04, indicating the market prices VKTX's pipeline optionality at a premium to some peers. Its D/E of 0.43 sits above most peers, which carry near-zero leverage, so its relative weakness is in capital structure rather than return profile. These gaps appear structural to the stage of development rather than temporary, though investors should verify against each company's pipeline stage.